+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Graves Disease Market - Global Forecast 2026-2032- Product Image
Graves Disease Market - Global Forecast 2026-2032- Product Image
New

Graves Disease Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 189 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674290
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Graves Disease Market is evolving through coordinated advances across diagnostics, therapy personalization, and digital healthcare, reshaping pathways for healthcare professionals, payers, and suppliers.

Market Snapshot

The Graves Disease Market grew from USD 678.55 million in 2025 to USD 717.23 million in 2026. It is projected to continue expanding at a CAGR of 5.92%, expected to reach USD 1.01 billion by 2032. Market momentum is sustained by shifts in clinical pathways, regulatory frameworks, and supply chain dynamics that collectively underpin diagnostic, therapeutic, and distribution strategies for Graves disease care.

Scope & Segmentation

This research report analyzes comprehensive facets of the Graves disease market across clinical, technological, and commercial domains:

  • Diagnostics: Covers physical examination, thyroid hormone assays, autoantibody panels, and advanced imaging modalities—emphasizing evolving diagnostic algorithms and site-of-care dynamics.
  • Treatments: Examines antithyroid drugs, symptomatic management with beta-blockers, and targeted interventions such as radioactive iodine therapy, focusing on regimen personalization and patient outcomes.
  • Demographics: Investigates adult, elderly, and pediatric populations, highlighting tailored workflows, risk profiles, and monitoring priorities.
  • Administration Routes: Outlines oral and intravenous options, exploring their influence on chronic management and acute intervention settings.
  • Distribution Pathways: Details the roles of hospital pharmacies, retail pharmacies, and the expanding presence of online pharmacy models in accessibility and adherence.
  • Regional Segments: Provides context on the Americas, Europe, Middle East & Africa, and Asia-Pacific, underlining unique regional regulations, payer structures, and health-system maturity levels.
  • Technological Innovations: Addresses advancements in assay sensitivity, digital monitoring, telemedicine, and integration of real-world evidence into clinical and commercial decision-making.

Key Takeaways

  • Integrated diagnostic algorithms are reducing delays and improving the appropriateness of treatment selections for Graves disease, supporting a more clinically rigorous approach across patient cohorts.
  • Personalized therapy is advancing through nuanced prescribing decisions that factor in comorbidities, patient preferences, and digital adherence monitoring to improve long-term disease control and engagement.
  • Value-based contracting and payer-driven evaluations are shaping treatment access, with a growing emphasis on outcome evidence and operational efficiency throughout the supply and reimbursement chains.
  • Digital health innovation is elevating the patient experience, offering new avenues for remote follow-up, medication adherence tracking, and clinician decision support systems—all critical in chronic disease management.
  • Stakeholders from clinical, commercial, and payer domains increasingly collaborate to align evidence generation, supply strategies, and patient-centric services in the evolving care continuum for Graves disease.

Tariff Impact

Policy-driven changes in trade tariffs introduce supply chain complexity, affecting the availability and pricing of diagnostics, therapeutic agents, and equipment components required for thyroid care. Health systems and distributors are adapting procurement and sourcing strategies, such as diversifying suppliers or increasing local sourcing, to safeguard care continuity. These cost and logistical pressures influence hospital and pharmacy operations, inform formulary and inventory decisions, and ultimately determine patient access and system stability during periods of global volatility.

Methodology & Data Sources

This report utilizes a rigorous, ethically grounded mixed-methods approach. Primary interviews with endocrinologists, laboratory directors, and procurement leaders provide frontline insights, while secondary literature reviews and analysis of clinical guidelines ensure robust operational validation. Qualitative data is triangulated with regulatory and market intelligence for comprehensive market understanding.

Why This Report Matters

  • Enables strategic alignment by mapping current and future trends in diagnostics, therapies, and distribution channels for effective stakeholder coordination.
  • Supports better operational planning through scenario analysis of tariff impacts and supply chain disruptions, aiding procurement and continuity decisions.
  • Guides investment by providing actionable segmentation across patient demographics, administration methods, and regional market dynamics in the Graves Disease Market.

Conclusion

Effective management of Graves disease relies on sustained innovation, integrated care models, and proactive response to market and policy developments. This research guides decision-makers in leveraging technology, segmentation, and coordinated strategies for improved patient outcomes and commercial resilience.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Graves Disease Market, by Diagnostics
8.1. Blood Tests
8.1.1. Thyroid-stimulating Hormone (TSH) Levels
8.1.2. Free T4 & T3 Levels
8.1.3. TSH Receptor Antibodies (TSH-RAb)
8.2. Imaging Tests
8.2.1. Thyroid Ultrasound
8.2.2. Radioactive Iodine Uptake
8.3. Physical Examination
9. Graves Disease Market, by Treatment Type
9.1. Antithyroid Medications
9.2. Radioactive Iodine Therapy
9.3. Surgical Interventions
10. Graves Disease Market, by Drug Class
10.1. Thionamides
10.1.1. Methimazole
10.1.2. Propylthiouracil
10.1.3. Carbimazole
10.2. Beta Blockers
10.3. Corticosteroids
11. Graves Disease Market, by Route Of Administration
11.1. Oral
11.2. Intravenous
12. Graves Disease Market, by Age Group
12.1. Pediatric
12.2. Adult
12.3. Geriatric
13. Graves Disease Market, by Line Of Therapy
13.1. First Line Therapy
13.2. Second Line Therapy
13.3. Third Line Therapy
14. Graves Disease Market, by End User
14.1. Hospitals
14.2. Clinics
14.3. Ambulatory Surgical Centers
14.4. Diagnostic Laboratories
15. Graves Disease Market, by Distribution Channel
15.1. Hospital Pharmacies
15.2. Retail Pharmacies
15.3. Online Pharmacies
16. Graves Disease Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Graves Disease Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Graves Disease Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Graves Disease Market
20. China Graves Disease Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. Abbott Laboratories
21.6. AdvanceCor GmbH
21.7. Amgen Inc.
21.8. Cadila Pharmaceuticals Limited
21.9. CORONA Remedies Limited
21.10. Daxia Healthcare Pvt Ltd.
21.11. Eris Lifesciences Ltd
21.12. F. Hoffmann-La Roche Ltd.
21.13. Immunovant, Inc. by Roivant Sciences Ltd.
21.14. Macleods Pharmaceuticals Ltd.
21.15. Merck KGaA
21.16. Novartis AG
21.17. Pfizer Inc.
21.18. Salvavidas Pharmaceutical Pvt. Ltd.
21.19. Siemens Healthineers AG
21.20. Steris Healthcare Pvt Ltd
21.21. Sun Pharmaceutical Industries Ltd
21.22. Synmedic Laboratories by Dhanuka Laboratories Limited
21.23. Teva Pharmaceutical Industries Ltd.
21.24. Thermo Fisher Scientific Inc.
21.25. Wellona Pharma
List of Figures
FIGURE 1. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GRAVES DISEASE MARKET SIZE, BY METHIMAZOLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GRAVES DISEASE MARKET SIZE, BY METHIMAZOLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GRAVES DISEASE MARKET SIZE, BY METHIMAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPYLTHIOURACIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPYLTHIOURACIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPYLTHIOURACIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GRAVES DISEASE MARKET SIZE, BY CARBIMAZOLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GRAVES DISEASE MARKET SIZE, BY CARBIMAZOLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GRAVES DISEASE MARKET SIZE, BY CARBIMAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GRAVES DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GRAVES DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GRAVES DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GRAVES DISEASE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GRAVES DISEASE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GRAVES DISEASE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GRAVES DISEASE MARKET SIZE, BY FIRST LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GRAVES DISEASE MARKET SIZE, BY FIRST LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GRAVES DISEASE MARKET SIZE, BY FIRST LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GRAVES DISEASE MARKET SIZE, BY SECOND LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GRAVES DISEASE MARKET SIZE, BY SECOND LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GRAVES DISEASE MARKET SIZE, BY SECOND LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIRD LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIRD LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIRD LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GRAVES DISEASE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GRAVES DISEASE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GRAVES DISEASE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GRAVES DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GRAVES DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GRAVES DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. EUROPE GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 160. EUROPE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 161. EUROPE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 162. EUROPE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 163. EUROPE GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. EUROPE GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 165. EUROPE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. EUROPE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. EUROPE GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 168. EUROPE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. EUROPE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 184. AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 185. AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 186. AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 187. AFRICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 188. AFRICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 189. AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. AFRICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 192. AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 209. ASEAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 210. ASEAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 211. ASEAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 212. ASEAN GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 213. ASEAN GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 214. ASEAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. ASEAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 216. ASEAN GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 217. ASEAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. ASEAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. GCC GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 221. GCC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 222. GCC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 223. GCC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 224. GCC GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 225. GCC GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 226. GCC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. GCC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 228. GCC GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 229. GCC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. GCC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. BRICS GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 245. BRICS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 246. BRICS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 247. BRICS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 248. BRICS GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 249. BRICS GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 250. BRICS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 251. BRICS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 252. BRICS GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 253. BRICS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. BRICS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 255. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. G7 GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 257. G7 GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 258. G7 GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 259. G7 GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 260. G7 GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 261. G7 GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 262. G7 GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. G7 GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 264. G7 GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 265. G7 GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. G7 GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 267. NATO GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. NATO GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 269. NATO GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 270. NATO GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 271. NATO GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 272. NATO GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 273. NATO GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 274. NATO GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 275. NATO GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 276. NATO GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 277. NATO GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 278. NATO GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 279. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 292. CHINA GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 293. CHINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 294. CHINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
TABLE 295. CHINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 296. CHINA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 297. CHINA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 298. CHINA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
TABLE 299. CHINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 300. CHINA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 301. CHINA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 302. CHINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 303. CHINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Graves Disease market report include:
  • Abbott Laboratories
  • AdvanceCor GmbH
  • Amgen Inc.
  • Cadila Pharmaceuticals Limited
  • CORONA Remedies Limited
  • Daxia Healthcare Pvt Ltd.
  • Eris Lifesciences Ltd
  • F. Hoffmann-La Roche Ltd.
  • Immunovant, Inc. by Roivant Sciences Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Siemens Healthineers AG
  • Steris Healthcare Pvt Ltd
  • Sun Pharmaceutical Industries Ltd
  • Synmedic Laboratories by Dhanuka Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Wellona Pharma

Table Information

Report AttributeDetails
No. of Pages189
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 717.23 Million
Forecasted Market Value ( USD ) by 2032 $ 1010 Million
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Graves' Disease (Overactive Thyroid) Market - Global Strategic Business Report - Product Image

Graves' Disease (Overactive Thyroid) Market - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Graves' Disease - Pipeline Insight, 2025 - Product Image

Graves' Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Goitre Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Goitre Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Carbimazole Market - Global Forecast 2026-2032 - Product Image

Carbimazole Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Graves' Orbitopathy- Pipeline Insight, 2025 - Product Image

Graves' Orbitopathy- Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Graves Disease Market

Graves Disease is a type of autoimmune disorder that affects the thyroid gland. It is the most common cause of hyperthyroidism, a condition in which the thyroid produces too much of the hormone thyroxine. Symptoms of Graves Disease include weight loss, increased appetite, rapid heart rate, and bulging eyes. Treatment typically involves medications to reduce the production of thyroxine, as well as radioactive iodine therapy to destroy the thyroid gland. Allergy and Immunology is a medical specialty that focuses on the diagnosis and treatment of allergies and immune system disorders. Allergy and Immunology specialists are trained to diagnose and treat Graves Disease, as well as other autoimmune disorders. They may also provide advice on lifestyle changes to help manage the condition. Companies in the Graves Disease market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.